OLUX E Drug Patent Profile

Which patents cover Olux E, and what generic alternatives are available?

Olux E is a drug marketed by Pharmobedient and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-two patent family members in sixteen countries.

The generic ingredient in OLUX E is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Olux E

A generic version of OLUX E was approved as clobetasol propionate by COSETTE on February 16^th, 1994.

Summary for OLUX E

International Patents:	22
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	5,598
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OLUX E
DailyMed Link:	OLUX E at DailyMed

Paragraph IV (Patent) Challenges for OLUX E

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OLUX E	Emulsion Foam	clobetasol propionate	0.05%	022013	1	2010-02-25

US Patents and Regulatory Information for OLUX E

OLUX E is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007		DISCN	Yes	No	8,460,641		Y

Expired US Patents for OLUX E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007	8,962,000
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007	6,730,288
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007	7,029,659

International Patents for OLUX E

See the table below for patents covering OLUX E around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	4603164
Russian Federation	2007111706	СПОСОБ ПОЛУЧЕНИЯ МИКРОЭМУЛЬСИЙ И СУБМИКРОННЫХ ЭМУЛЬСИЙ И КОМПОЗИЦИИ НА ИХ ОСНОВЕ
World Intellectual Property Organization (WIPO)	0015193
Japan	5612263
Russian Federation	2381023	СПОСОБ ПОЛУЧЕНИЯ МИКРОЭМУЛЬСИЙ И СУБМИКРОННЫХ ЭМУЛЬСИЙ И КОМПОЗИЦИИ НА ИХ ОСНОВЕ (METHOD FOR MAKING MICROEMULSIONS AND SUBMICRON EMULSIONS AND BASED COMPOSITION)
Argentina	051197	UN PROCEDIMIENTO PARA OBTENER UNA MICROEMULSION Y SUB-MICRON EMULSION Y COMPOSICIONES
Israel	181632	תכשירים ותהליך להכנת מיקרואמולסיה ואמולסיה תת-מיקרונים (Microemulsion and sub-micron emulsion process and compositions)

OLUX E Market Analysis and Financial Projection

Last updated: April 25, 2026

OLUX E: Market Dynamics and Financial Trajectory

OLUX E is a topical foam formulation of olux (clobetasol propionate) marketed for inflammatory dermatoses. The competitive set is dominated by other topical corticosteroid brands, generic clobetasol products, and formulation rivals (foam, spray, gel, ointment) with different payer-preferred profiles and patient adherence advantages. OLUX E’s financial trajectory is shaped less by novelty and more by (1) generic encroachment on clobetasol, (2) channel mix across retail vs specialty-like channels for dermatology, and (3) payer rules that reward lower-cost NDCs and preferred dosage forms.

What is OLUX E and where does it sit in the dermatology market?

OLUX E (clobetasol propionate topical foam) targets dermatoses requiring a high-potency topical steroid. In the US market for topical corticosteroids, the segment is mature, price-competitive, and highly sensitive to formulary placement and step therapy.

Positioning and demand drivers

• Therapy class: high-potency topical corticosteroid (dermatology)
• Form factor: foam (typically chosen for scalp and hairy areas and perceived ease-of-use versus ointments/creams)
• Clinical pattern: short courses are common, reducing “chronic” consumption volume and making the product’s revenue more dependent on new starts, formulary access, and retention of prescriber preference.

Competitive structure

• Brand-to-generic pressure: clobetasol is widely available as generics. Brand products maintain pricing power only when payers enforce fewer substitutes or the specific formulation is preferred.
• Formulation competition: other clobetasol dosage forms and other high-potency corticosteroids compete on dosing frequency, vehicle tolerability, and adherence.

How do payer and channel dynamics affect OLUX E revenue?

Topical steroids trade primarily through retail pharmacy distribution, with dermatology-driven prescribing in primary care and specialty channels. Revenue trajectory typically tracks with formulary access and claim mix.

Payer mechanics that matter

• Preferred drug lists (PDLs): generics and lower-cost NDCs often receive preferred status.
• Step edits / utilization management: plans may require trial of lower-cost high-potency agents or generics before covering a specific branded foam.
• Dosage-form edits: even with the same active ingredient, plans can force selection of a particular vehicle (ointment vs foam vs solution) tied to plan contracting and budget impact.

Channel dynamics

• Retail fill volatility: shifts in formulary status can move demand quickly.
• Real-world prescriber behavior: once clinicians settle on a preferred foam or a lower-cost generic, brand share tends to drift without marketing or new evidence.

What are the market forces shaping pricing power for clobetasol foam brands?

The financial trajectory of a branded clobetasol foam is usually constrained by economics of generics and by substitution across dosage forms.

Key market forces

1. Generic substitution of clobetasol
   • When multiple AB-rated equivalents exist, payer and pharmacy incentives push conversion away from brands.
2. Vehicle-driven preference
   • Foam can win subset demand (scalp, hair-bearing areas, perceived cosmetic acceptability), but this only partially offsets generic price pressure.
3. Contracting and rebates
   • Brand net prices depend on rebate intensity, which increases when formularies add or favor generics.
4. Utilization management
   • Prior authorization and step therapy reduce brand volumes even when prescriptions are written.

Implication for OLUX E

• OLUX E’s unit economics are typically pressured by net price compression and volume dilution as plan options expand and generic NDC coverage broadens.
• The product’s “edge” is durability of foam-specific preference and continued formulary access.

How has the broader competitive landscape evolved for topical high-potency steroids?

The topical corticosteroid market has followed a predictable arc: brand introduction, expansion, then generic and biosystem-like substitution dynamics at the class level. For clobetasol-based products, the market generally trends toward:

• Lower average selling prices for the active class as more generics enter.
• More granular payer rules that optimize costs by dosage form and manufacturer contracting.
• Increased focus on patient adherence and vehicle usability in formularies.

What this means for financial trajectory

• Branded foam products usually show:
  • Reduced share over time relative to generics
  • Increasing dependence on payer exceptions and brand-specific coverage windows
  • Periodic step-downs in net sales around formulary updates

What is the likely financial trajectory pattern for OLUX E?

A mature topical steroid brand typically follows a trajectory with three phases:

1. Peak-to-declining transition: brand share holds while coverage is broad.
2. Compression phase: formularies prefer generics and non-foam alternatives; net pricing falls.
3. Stabilization at a reduced base: remaining demand concentrates in prescriber niches, patient-specific preference, and plan exceptions.

For OLUX E, the trajectory is best modeled as:

• Revenue trending down or flat at best as generic clobetasol expands and competitive vehicles widen.
• Margin sensitivity to rebates and acquisition costs because net price declines faster than fixed overhead.
• Dependence on contracting outcomes (rebate levels, tier status, formulary residency) rather than on incremental clinical differentiation.

Where do the biggest profit levers sit: price, volume, or mix?

For OLUX E, the profit equation is usually dominated by mix and payer economics rather than product innovation.

Profit levers

• Net price: most sensitive to formulary tier changes and rebate pressure.
• Volume: tied to prescriptions converted into covered NDCs.
• Mix: foam vs other clobetasol vehicles impacts both plan coverage and patient adherence outcomes, shifting effective coverage and persistence.

Financial and operational considerations for investors and R&D planners

Even without a granular public quarter-by-quarter OLUX E revenue table, the investment logic for a topical brand is consistent with observed class dynamics:

1) Brand value erodes unless coverage persists

• Once clobetasol generics become preferred across major plans, branded products typically face a “coverage cliff” in net sales.

2) Foam helps but does not reset the generic math

• Foam can be a differentiator in patient usability, but it does not prevent substitution when the active ingredient is generic-available.

3) Legal and exclusivity events matter, but product-level differentiation is limited

• For existing molecules, exclusivity and patent coverage (if any) are often less decisive than formulary access.

How does OLUX E compare with substitutes that affect revenue?

Below is a practical substitution map that drives claims competition.

Substitutes that can displace OLUX E	What payers reward	Typical impact on OLUX E
Generic clobetasol propionate (AB-rated)	Lower cost, preferred tier	Volume erosion and net price pressure
Other clobetasol vehicles (cream/ointment/solution)	Plan contracts by vehicle	Mix shift away from foam
Other high-potency topical corticosteroids	Brand or generic preference by plan	Additional substitution channel
Lower-utilization management alternatives	Step therapy pathways	Prior-authorization-driven demand loss

What market signals should be tracked for OLUX E?

To forecast financial trajectory in a mature topical market, track signals tied directly to formulary and utilization:

1. Formulary tier status changes (PDL updates, step edits)
2. NDC-level share shifts among clobetasol foams and generics
3. Retail claim counts and script volume in dermatology segments
4. Net price and rebate changes disclosed at company level
5. Switching behavior after new generic introductions or contract renegotiations

What are the decision points for business strategy tied to OLUX E?

If the objective is to protect revenue

• Focus contracting strategy on keeping foam-specific coverage on key PDLs
• Target adherence and prescriber preferences for scalp and hair-bearing applications
• Use lifecycle marketing that reinforces differentiation in real-world usability, not molecule novelty

If the objective is to predict decline

• Model revenue as a function of:
  • generic share growth across top plans
  • tier downgrades that increase out-of-pocket costs
  • vehicle preference loss if alternative dosage forms win contracts

Key Takeaways

• OLUX E operates in a mature, generic-exposed topical corticosteroid market where financial outcomes hinge on formulary access, step edits, and NDC-level substitution rather than clinical innovation.
• Foam can preserve a niche, but it does not prevent AB-rated generic clobetasol displacement, which typically drives net sales decline or stagnation and margin compression over time.
• The most actionable forecasting inputs are PDL tier status, claim share by NDC/vehicle, and rebate-driven net pricing trends tied to contracting.

FAQs

1) Is OLUX E protected from generic clobetasol substitution?
OLUX E competes against widely available generic clobetasol products; in practice, ongoing revenue depends on payer coverage of the branded foam and related contracting.

2) Does foam formulation materially change payer outcomes for clobetasol?
Foam can influence patient and prescriber preference and can affect formulary decisions by vehicle, but payers still optimize for cost at the NDC level.

3) What drives OLUX E demand: dermatologist vs primary care?
OLUX E demand is generated through routine prescribing for dermatologic inflammation across primary care and dermatology; claim volume is highly sensitive to coverage rules that apply uniformly across prescriber types.

4) What is the most likely financial pattern for OLUX E over time?
A typical pattern is erosion from generic displacement, with stabilization only if formulary positioning and foam-specific preference retain meaningful coverage.

5) What indicators best predict OLUX E sales direction?
Track formulary tier placement, step edits, NDC share shifts for clobetasol foams vs generics, and net price changes driven by rebates and contracting.

---

References

[1] US Food and Drug Administration. Drug Approval Reports / Labels (OLUX E, clobetasol propionate topical foam). FDA.